HOME >> BIOLOGY >> NEWS
Joslin Diabetes Center in Boston establishes first affiliate in Canada

BOSTON-October 19, 2006-Joslin Diabetes Center, the global leader in diabetes research, care and education, has announced its partnership with Acadie-Bathurst Health Authority (ABHA) in New Brunswick, Canada. The new affiliate, which is located at Chaleur Regional Hospital, is Joslin's first Canadian Affiliate.

The new Joslin Affiliate is an Education Affiliate, so all of Joslin's premier education programs and services are shared with the institution. This will complement the endocrine services offered by Dr. Farrukh Khan a board-certified endocrinologist who serves as medical director.

"There is no doubt in my mind that the establishment of a Joslin Diabetes Center Education Affiliate right here in Bathurst is a major coup for residents of the region and the entire population of New Brunswick," stated Gabriel Godin, chair of the ABHA board of trustees.

"According to the Canadian Diabetes Association, more than 5.4 percent of the people in New Brunswick have diabetes, and as many as one-third of the population has diabetes but don't know they have the disease," said Judith Eyres Goodwin, director of Joslin's Affiliated Centers Program. "We look forward to working with the professionals at Chaleur Regional Hospital to bring Joslin's integrated, state-of-the-art education programs and services to people with diabetes and related conditions in the region."

"Our staff have received training from Joslin Diabetes Center in Boston to ensure that they follow the organization's standards closely in providing education to patients with diabetes in the Chaleur region and the Acadian Peninsula," said Alice Hbert, director of nursing for the ABHA.


'"/>

Contact: Jenny Eriksen
jenny.eriksen@joslin.harvard.edu
617-732-2415
Joslin Diabetes Center
19-Oct-2006


Page: 1

Related biology news :

1. Joslin study indicates insulin receptors play a critical role in promoting islet growth
2. Joslin researchers discover a surprising culprit in the search for causes of diabetic birth defects
3. Joslin study reveals how a specific fat type can protect against weight gain and diabetes
4. Joslin discovers protein that causes blood vessel leakage and swelling with diabetic retinopathy
5. Joslin-led study uncovers role of appetite hormone MCH in insulin production
6. Joslin Diabetes Center study examines insulin pump therapy in adolescents
7. Walgreens and Joslin Diabetes Center form broad alliance to improve diabetes outcomes
8. Joslin awards Victory Medal to New York man living 75 years with type 1 diabetes
9. Joslins new book demystifies nutrition and meal planning for people with diabetes
10. Joslin study refutes recent report that bone marrow can replenish female oocytes
11. Joslin discovers signs of residual islet cell function in people with long-term type 1 diabetes

Post Your Comments:
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used ... measures the overall facial feature of a person ... distance between eyes. Facial recognition is used for ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
(Date:12/10/2014)... , Dec. 9, 2014 CIE San ... catalyst that provides the connective tissue that enhances care ... them to easily share client-level information; earned a second ... expand to organizations serving seniors aging in community and; ... partner on December 11 th 4-6p. ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
(Date:12/17/2014)...  Vermillion, Inc. (NASDAQ: VRML ), a ... the next step in its expanded strategy to rebuild ... the naming of current Chief Operating Officer, Valerie ... current Chairman of the Board and CEO James ... changes are effective January 1, 2015. "Jim ...
(Date:12/17/2014)... , Dec. 17, 2014 Tigercat Pharma, ... 2 study evaluating the investigational oral NK-1 receptor ... with severe, chronic itch who are unresponsive or ... including topical steroids and antihistamines. ... Visual Analog Scale (VAS) itch score from baseline, ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel , ... BCLI ), a leading developer of adult ... wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was awarded a ... Office of the Chief Scientist (OCS).  This ... receipt of grant support from the Office of the ...
(Date:12/15/2014)... 15, 2014  Origin Agritech Limited (NASDAQ GS: SEED) (" ... of crop seeds in China , today ... year 2014 ended September 30, 2014, before the market opens ... host a teleconference on January 8, 2015, at 8:00 a.m. ... to discuss the results. To participate in the call, please ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3
Cached News: